TG Therapeutics | TGTX - Cash And Equivalent


TG Therapeutics reported $199.51M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.23B 400M Dec/2025
Alaunos Therapeutics USD 1.94M 941K Sep/2025
Amgen USD 9.13B 316M Dec/2025
Ardelyx USD 68M 25.28M Dec/2025
Arrowhead Research USD 201.64M 112.94M Dec/2025
Bayer EUR 5.9B 1.34B Sep/2025
Biogen USD 3.01B 854.3M Dec/2025
Corcept Therapeutics USD 120.49M 4.64M Dec/2025
Curis USD 10.14M 10.14M Jun/2025
Gilead Sciences USD 7.56B 234M Dec/2025
Infinity Pharmaceuticals USD 17.75M 7.99M Jun/2023
J&J USD 21.69B 1.98B Mar/2026
Karyopharm Therapeutics USD 60.54M 22.87M Dec/2025
Novartis USD 11.44B 1.88B Dec/2025
Novavax USD 240.63M 27.39M Dec/2025
PTC Therapeutics USD 984.65M 312.03M Dec/2025
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Regeneron Pharmaceuticals USD 2.96B 15.9B Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025
TG Therapeutics USD 199.51M 21.2M Dec/2025
Verastem USD 204.99M 67.28M Dec/2025
Vertex Pharmaceuticals USD 6.61B 321.1M Dec/2025